(ACRX) |
| 0 (0%) 10-10 16:19 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.61 |
| Resistance 1: | 1.32 |
| Pivot price: | 1.30 |
| Support 1: | 0.84 |
| Support 2: | 0.70 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -16830000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -147.885 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -2.00 |
| Return on Assets (ttm) | 828.2 |
| Return on Equity (ttm) | -32.2 |
Company news
Wed, 08 Nov 2023
AcelRx Pharmaceuticals: Q3 Earnings Snapshot - qz.com
Wed, 05 Apr 2023
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals - PR Newswire
Thu, 30 Mar 2023
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update - PR Newswire
Mon, 10 Jan 2022
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics - PR Newswire
Wed, 06 Oct 2021
AcelRx Pharmaceuticals (ACRX) CEO Vincent Angotti Details Near Term Revenue Prospects - The Wall Street Transcript
Tue, 27 Jul 2021
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
